ALK-positive non-small cell lung cancer: Mechanisms of resistance and emerging treatment options

Cancer ◽  
2014 ◽  
Vol 120 (16) ◽  
pp. 2392-2402 ◽  
Author(s):  
Conor E. Steuer ◽  
Suresh S. Ramalingam
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Treatment Options ◽  
Small Cell ◽  
Small Cell Lung ◽  
Mechanisms Of Resistance ◽  
Alk Positive

scholarly journals 155P Predictors of treatment response in ALK-positive metastatic non-small cell lung cancer

2021 ◽  
Vol 16 (4) ◽  
pp. S782
Author(s):  
I. Dogan ◽  
M. Gürbüz ◽  
N. Paksoy ◽  
F. Ferhatoğlu ◽  
S. Vatansever ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Treatment Response ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Alk Positive

Complete response after ceritinib treatment in non-small cell lung cancer in an elderly patient

2020 ◽  
Vol 26 (8) ◽  
pp. 2031-2033
Author(s):  
Nilay Sengul Samanci ◽  
Emir Celik ◽  
Burak Akovalı ◽  
Sait Sager ◽  
Fuat Hulusi Demirelli
Keyword(s):  
Lung Cancer ◽  
Elderly Patient ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Complete Response ◽  
Small Cell ◽  
Small Cell Lung ◽  
Anaplastic Lymphoma ◽  
Stage 4 ◽  
Alk Positive

Introduction Ceritinib is a selective second-generation ALK inhibitor that is highly sensitive to echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase (EML4-ALK) molecule. Case report In this paper, we report a 68-year-old female that was diagnosed with stage 4 ALK-positive non-small cell lung cancer (NSCLC). Management and outcome: She was treated with crizotinib first-line, cisplatin and gemcitabine as second-line. And for third-line, ceritinib was started. She had complete response over 3.5 years under ceritinib treatment. And she is still receiving ceritinib with no adverse event. Discussion Cases achieving complete response with ceritinib treatment are rare. In this paper, we aimed to emphasize the complete response in stage 4 NSCLC in an elderly patient.

scholarly journals The Central Nervous System as a Sanctuary Site in ALK-Positive Non–Small-Cell Lung Cancer

2013 ◽  
Vol 8 (12) ◽  
pp. 1570-1573 ◽  
Author(s):  
Justin F. Gainor ◽  
Sai-Hong Ignatius Ou ◽  
Jennifer Logan ◽  
Lawrence F. Borges ◽  
Alice T. Shaw
Keyword(s):  
Lung Cancer ◽  
Central Nervous System ◽  
Nervous System ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
The Central Nervous System ◽  
Alk Positive

scholarly journals MA07.03 Alectinib (ALC) versus Crizotinib (CRZ) in ALK-Positive Non-Small Cell Lung Cancer (ALK+ NSCLC): Primary Results from Phase III Study (J-ALEX)

2017 ◽  
Vol 12 (1) ◽  
pp. S378-S379 ◽  
Author(s):  
Young Kim ◽  
Toyoaki Hida ◽  
Hiroshi Nokihara ◽  
Masashi Kondo ◽  
Koichi Azuma ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Phase Iii ◽  
Small Cell Lung ◽  
Phase Iii Study ◽  
Alk Positive

Current and evolving treatment options for limited stage small cell lung cancer

2006 ◽  
Vol 18 (2) ◽  
pp. 162-172 ◽  
Author(s):  
Carrie B Lee ◽  
David E Morris ◽  
Daniel B Fried ◽  
Mark A Socinski
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Treatment Options ◽  
Small Cell ◽  
Small Cell Lung ◽  
Limited Stage
Sign in / Sign up

Export Citation Format

Share Document